サンプル依頼リスト カート
  • English
  • Korean
表紙：高尿酸血症の世界市場-2023年～2030年
市場調査レポート
商品コード
1345436

高尿酸血症の世界市場-2023年～2030年

Global Hyperuricemia Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
高尿酸血症の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の高尿酸血症市場は、2022年に16億米ドルに達し、2023-2030年の予測期間中にCAGR 5.4％で成長し、2030年には34億米ドルに達すると予測されています。

血液中に尿酸が過剰に含まれると、高尿酸血症が発生します。高尿酸血症は自覚症状はありませんが、痛風や腎臓結石などの病気を誘発する可能性があります。プリン体は様々な食事に含まれる物質で、体内で分解され、製品別として尿酸が作られます。

プリン体を多く含む食事や飲料の摂取を控えることで、血液中の尿酸の量を減らすことができます。この減少により、腎臓は再び尿酸をより効率的にろ過できるようになります。男性に比べ、女性は高尿酸血症の有病率がかなり低く、50歳未満では1～2％、50歳以上では約3％です。

さらに、痛風は最近の研究によると、がん、乾癬、心房細動、血栓塞栓症、COPD、血栓塞栓症との関連が指摘されています。高尿酸血症と痛風は、その深刻な合併症と健康関連QOLへの重大な影響から、公衆衛生上の懸念事項として注目されるようになっています。高尿酸血症の有病率は、急速な経済発展やライフスタイルの変化に伴って著しく上昇しています。

ダイナミクス

製品承認と臨床試験の増加

高尿酸血症の根本的な原因や痛風のような関連疾患の分子メカニズムに関する継続的な調査の結果、新たな治療目的や治療方法が見出されています。このため、新たに創製された薬剤や治療法が成功を収めることが可能になっています。

例えば、2023年1月、米国食品医薬品局（USFDA）はザイダス・ライフサイエンス社に対し、フェブキソスタット錠40mgと80mgの販売を最終承認しました。基準収載薬のウロリック錠は、承認されたフェブキソスタット錠40mgと80mgと同等です。フェブキソスタット錠は、アロプリノール治療が無効または不適格な痛風患者における高尿酸血症（血中尿酸値が高い状態）を改善することを目的としています。

さらに、2023年6月、痛風および高尿酸血症に関連するその他の疾患の治療薬の開発・商業化に注力するFortress Biotech, Inc.の子会社であるUrica Therapeutics, Inc.より、米国における健康なボランティアを対象としたドチヌラドの第1相臨床試験のトップラインデータが配布されました。ドチヌラド（新規尿酸トランスポーター）は、どの投与量においても重篤な副作用は報告されておらず、安全性と忍容性が実証されました。このように、臨床試験の拡大と製品承認が市場を後押ししています。

高齢者人口の増加

高齢化に伴い、腎臓の機能が低下する可能性があります。尿酸をろ過して体外に排泄することは腎臓の重要な機能です。腎臓の機能が低下すると、尿酸が体外に排泄される量が少なくなり、血液中の尿酸値が上昇し、高尿酸血症の兆候となります。

高齢になると、食生活の嗜好や運動量が変化することがあります。加齢に伴い、過度の飲酒やプリン体を多く含む食事など、不健康な食事パターンが多くなります。これらの要素が、高齢者の尿酸値上昇の原因となっている可能性があります。

このように、高齢化人口が増加していることも、市場の急拡大に寄与しています。例えば、Eurostatによると、2022年1月のEU人口は4億4,670万人と推定され、そのうち65歳以上の高齢者は21.1％で、前年比0.3ポイント増、10年前と比較すると3.1ポイント増となっています。

さらに、国連（UN）の新しい報告書によると、世界全体で65歳以上の高齢者の数は、今後30年間で2倍に増加すると予想されています。高齢者人口は2050年には16億人に達し、世界人口の16％を超えると予想されています。このように高齢者人口が増加することにより、市場の成長が促進されます。

高尿酸血症診断に関する認識不足

高尿酸血症が健康に及ぼすリスクは、医療専門家を含む多くの人々に十分に認識されていない可能性があります。このような知識不足は、診断の遅れや医療の質の低下を招く可能性があります。さらに、高尿酸血症は、特に痛風や他の関連疾患の既往歴のない人では、標準的な健康診断で発見されることはほとんどありません。定期的な検査を受けなければ、患者は尿酸値の上昇に気づかないかもしれません。医療従事者によっては、特定の症状や高尿酸血症の危険因子を持たない人に優先的に検査を行わない場合もあります。そのため、早期発見や早期教育の機会が失われる可能性があります。このように、前述の要因は市場拡大の妨げとなっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 製品承認と臨床試験の増加
      • 高齢者人口の増加
  • 抑制要因
      • 高尿酸血症診断に対する認識不足
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • 原発性
  • 二次性

第8章 年齢層別

  • 児童
  • 成人

第9章 薬剤タイプ別

  • キサンチンオキシダーゼ阻害薬
  • 非ステロイド性抗炎症薬
  • 副腎皮質ステロイド
  • その他

第10章 投与経路別

  • 経口剤
  • 注射剤

第11章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第14章 企業プロファイル

  • Arthrosi Therapeutics, Inc
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Dr.Reddy's
  • Urica Therapeutics, Inc
  • Zydus Lifesciences
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Hikma Pharmaceuticals Plc
  • Mylan N.V.
  • AstraZeneca Plc
  • Sun Pharmaceutical Industries Ltd

第15章 付録

目次
Product Code: PH6782

Overview

Global Hyperuricemia Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 3.4 billion by 2030, growing with a CAGR of 5.4 % during the forecast period 2023-2030.

When the bloodstream contains an excessive amount of uric acid, hyperuricemia occurs. Although it doesn't have any symptoms, it can induce diseases like gout or kidney stones. Purine, a substance found in a variety of meals, is broken down by the body to create uric acid as a byproduct.

The amount of uric acid in the blood can be decreased by consuming fewer purine-rich meals and beverages. The kidneys can once again filter uric acid out more efficiently because to this lowering. Compared to men, women have a substantially lower prevalence of hyperuricemia, with 1-2% of those under the age of 50 and about 3% of those over the age of 50.

Moreover, gout has been linked to cancer, psoriasis, atrial fibrillation, thromboembolism, COPD, and thromboembolism, according to recent studies. Due to its serious complications and significant impact on health-related quality of life, hyperuricemia and gout have come to prominence as a public health concern. The prevalence of hyperuricemia has risen significantly as a result of rapid economic development and lifestyle changes.

Dynamics

Increasing the Product Approvals and Clinical trails

Novel objectives and paths for intervention have been found as a result of ongoing study into the underlying causes of hyperuricemia and the molecular mechanisms of related disorders like gout. This makes it possible for newly created medications and treatments to become successful.

For instance, in January 2023, The US Food and Drug Administration (USFDA) gave final approval to Zydus Lifesciences company to market Febuxostat tablets, 40 mg and 80 mg. The reference listed medicine Uloric pills are equivalent to the approved Febuxostat tablets, 40 mg and 80 mg. The purpose of febuxostat tablets is to reduce hyperuricemia (high levels of uric acid in the blood) in gout patients who have either undergone unsuccessful allopurinol treatment or are ineligible for allopurinol therapy.

Additionally, in June 2023, Topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the United States has been distributed by Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia. With no severe adverse effects reported at any dose level, dotinurad (a new urate transporter) was demonstrated to be safe and well tolerated. Thus, the expansion of clinical trials and product approvals fuels the market.

The Increasing Geriatric Population

The function of the kidneys can decrease as ageing population. Filtering and excreting uric acid from the body is a critical function of the kidneys. Reduced kidney function can result in less uric acid being excreted from the body, which causes uric acid levels in the blood to rise and is a sign of hyperuricemia.

Aged persons may encounter changes in their dietary preferences and levels of physical activity. With aging, unhealthy eating patterns like drinking excessive alcohol or purine-rich meals become more prevalent. These elements may be responsible for higher uric acid levels in aged people.

Thus, the aging population is growing, which also contributes to the market's rapid expansion. For instance, according to Eurostat, the EU population in January 2022, was estimated to be 446.7 million, out of which 21.1% were Older individuals aged 65 or over indicating an increase of 0.3 percentage points (pp) to the previous year and an increase of 3.1 pp compared with a decade earlier.

In addition, according to a new report by the United Nations (UN), the number of individuals aged 65 years or above globally is anticipated to increase two folds in the next 30 years. The geriatric population is expected to attain 1.6 billion in 2050, making up over 16% of the world population. By thus increasing the geriatric population will drive the market growth.

Lack of Awareness about Hyperuricemia Diagnosis

The risks to health linked to hyperuricemia may not be fully recognized by many people, including medical experts. This lack of knowledge may result in a delayed diagnosis and poor care. Furthermore, hyperuricemia is rarely detected during standard medical exams, especially in people without a known history of gout or other related disorders. Patients might not be aware of their increased uric acid levels without routine testing. Some medical professionals might not give individuals who don't have certain symptoms or risk factors for hyperuricemia testing priority. Missed chances for early detection and education may come from this. Thus, the previous factors hinder market expansion.

Segment Analysis

The global hyperuricemia market is segmented based on type, age group, drug type, route of administration, distribution channel and region.

Xanthine Oxidase Inhibitors are Needed for Treatment

A class of drugs called Xanthine Oxidase Inhibitors (XO Inhibitors) is used to treat hyperuricemia, a disorder indicated by high amounts of uric acid in the blood. Hyperuricemia can cause uric acid crystals to develop, which can subsequently build up in joints and cause painful inflammation that could eventually result in diseases like gout.

Targeting the xanthine oxidase enzyme, which is essential for the synthesis of uric acid, is how XO inhibitors function. The enzyme xanthine oxidase is in charge of turning the uric acid precursors hypoxanthine and xanthine into uric acid. The body produces less uric acid when this enzyme is inhibited, which lowers the total levels of uric acid in the circulation. XO Inhibitors work by blocking this enzyme. It has been demonstrated that XO inhibitors are efficient at reducing uric acid levels and treating the signs and symptoms of hyperuricemia and gout. They are well-researched drugs with a successful track record in therapeutic use. Thus, these mentioned factors aid in accelerating segment expansion.

Geographical Penetration

Prevalence of the Diseases in the North American Region

Due to factors such as an aging population, an increase in obesity cases, technological improvements, and company strategies, North America is anticipated to hold the majority of the market over the forecast period. For instance, insulin resistance, a disorder in which the body's cells cannot respond to insulin, a hormone that aids in blood sugar regulation, is frequently linked to obesity.

Increased blood insulin levels brought on by insulin resistance may impair the kidneys' capacity to eliminate uric acid. Uric acid levels may increase as a result. As a result, the market may grow faster in the area due to the rise in obesity. For instance, according to healthline media stated that, over 42% of American adults are thought to be obese, while 30.7% are thought to be overweight. Overweight or obese conditions affect more than two thirds of American people overall.

Ages 40 to 59 are when adults are most likely to be obese. In actuality, obesity affects more than 44% of adults in this age range. In the meantime, 41.5% of individuals over the age of 60 and 39.8% of adults between the ages of 20 and 39 are obese. Thus, all of those variables accelerate market expansion in the region.

COVID-19 Impact Analysis

Hyperuricemia and catabolism can both be increased by COVID-19. By altering renal autoregulation, preventing endothelial cells from proliferating, inducing cell death, triggering the pro-inflammatory cascade, and causing crystal deposition, uric acid (UA) has the potential to harm the kidneys. The epidemic has put a burden on healthcare resources, causing non-urgent medical appointments, such as routine check-ups and screenings, to be postponed or delayed. Missed chances to diagnose hyperuricemia could arise from this. Some people avoid going to medical facilities because of lockdowns, limitations, and fear of spreading the virus. This may make it more difficult for them to acquire normal medical treatment or have their hyperuricemia reviewed.

By Type

  • Primary
  • Secondary

By Age Group

  • Children
  • Adults

By Drug Type

  • Xanthine Oxidase Inhibitors
  • Nonsteroidal Anti-Inflammatory Drugs
  • Corticosteroids
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In April 2023, in the HAMANGO-C trial, the efficacy of vitamin C in treating hyperuricemia and gout is examined. In order to ascertain the impact of vitamin C supplementation on blood urate levels in Hmong people with or without gout, researchers at the University of Minnesota in the United States have started a study called "the Hmong Microbiome and Gout, Obesity, Vitamin C (HMANGO-C)".
  • In December 2021, patient enrollment in a global phase 2b study of AR882, a novel medication candidate from Arthrosi Therapeutics, Inc., a clinical-stage biotech company, was announced. For the treatment of hyperuricemia in gout patients, especially those with chronic, refractory tophaceous gout, AR882 is a novel uricosuric drug now undergoing clinical research.

Competitive Landscape

The major global players in the market include: Arthrosi Therapeutics, Inc, Dr.Reddy's, Urica Therapeutics, Inc, Zydus Lifesciences, Takeda Pharmaceutical Company Limited, Novartis AG, Hikma Pharmaceuticals Plc, Mylan N.V., AstraZeneca Plc, Sun Pharmaceutical Industries Ltd and among others.

Why Purchase the Report?

  • To visualize the global hyperuricemia market segmentation based on type, age group, drug type, route of adminstration, distribution channel and region,as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of hyperuricemia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global Hyperuricemia market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by Drug Type
  • 3.4. Snippet by Route of Administration
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing the product approvals and clinical trails
      • 4.1.1.2. The increasing geriatric population
  • 4.2. Restraints
      • 4.2.1.1. Lack of awareness about hyperuricemia diagnosis
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Primary*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Secondary

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Children *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adults

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Xanthine Oxidase Inhibitors *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Nonsteroidal Anti-Inflammatory Drugs
  • 9.4. Corticosteroids
  • 9.5. Others

10. By Route of Administration

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Oral*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Injectable

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail pharmacies
  • 11.4. Online pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.9.1. Germany
      • 12.3.9.2. UK
      • 12.3.9.3. France
      • 12.3.9.4. Italy
      • 12.3.9.5. Spain
      • 12.3.9.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Arthrosi Therapeutics, Inc*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Dr.Reddy's
  • 14.3. Urica Therapeutics, Inc
  • 14.4. Zydus Lifesciences
  • 14.5. Takeda Pharmaceutical Company Limited
  • 14.6. Novartis AG
  • 14.7. Hikma Pharmaceuticals Plc
  • 14.8. Mylan N.V.
  • 14.9. AstraZeneca Plc
  • 14.10. Sun Pharmaceutical Industries Ltd

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us